American Oriental Bioengineering, Inc. (AOBI)

Market Cap	88.00 +144.4%
Revenue (ttm)	121.58M -10.2%
Net Income	-91.02M
EPS	-1,243.22
Shares Out	72.99K
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	500
Open	0.0012
Previous Close	0.0011
Day's Range	0.0012 - 0.0012
52-Week Range	0.0011 - 0.0012
Beta	0.05
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About AOBI

American Oriental Bioengineering, Inc. engages in the development, manufacture, and commercialization of various pharmaceutical and healthcare products. The company primarily provides prescription pharmaceutical products, including Shuanghuanglian Lyophilized Injection Powder under the SHL brand for the treatment of flu symptoms, such as high fever, cough, and sore throat, as well as upper respiratory infections, mild pneumonia, bronchitis, and tonsillitis; and Cease Enuresis Soft Gel under the CE Gel brand to alleviate bedwetting. It also offe...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Shujun Liu
• Employees: 3,719
• Stock Exchange: OTCMKTS
• Ticker Symbol: AOBI

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Aug 10, 2026

Data Sources Report a data error